Tempest Therapeutics (TPST) Q3 2026 earnings review

Tempest cut spending, but new licence fees exceed its cash

Tempest Therapeutics, a tiny developer of cancer and immune-disease drugs, signed up for bills far larger than its cash. It cut costs after laying off nearly all its staff. By our math, new contracts lift spending back near last year's level by the fourth quarter. It ended September with $0.9 million, but its new licence from Chinese partner Senlang costs $10 million in year one.

At a glance
Operating loss$2.8M down 21.5% from a year ago
Cash at the end of September$0.9M $7.7M at the end of 2025
First-year fees owed to Senlang and Factor$15M about 17 times cash on hand
Spending outlookNew administrative costs to stay near current levels

โš–๏ธ Verdict: ๐Ÿ”ด Bearish

The story got worse, because Tempest took on yearly fees that its own filing says it cannot fund. The good news: the licence adds a blood-cancer treatment already tested in patients, and its own China trial should start this quarter.

The question now is whether Tempest can raise money fast enough to keep the licence and its Nasdaq listing. Either early data attract new investors, or it keeps selling small batches of shares that dilute owners and still fall short. Nasdaq's ruling in the coming weeks and the first blood-cancer results at an upcoming conference will settle it.

๐Ÿ‚ Bull Case

๐ŸŸข PRODUCT

Tempest Licensed a Myeloma Treatment Already in Patients

In November Tempest took up its option to license technology from Senlang, a Chinese company that develops CAR-T treatments. These treatments re-engineer a patient's immune cells to attack disease. The licence covers every market outside Greater China.

Its lead candidate, TPST-4903, aims at two markers on the cells of multiple myeloma, a blood cancer, and is in a first-stage human study. The US biotech said early results showed "encouraging preliminary clinical responses" and expects to present them at a medical conference. It gave no patient count or response rate, so outsiders cannot judge the data yet.

What to watch: the conference presentation, which Tempest has not dated. Lasting responses across a meaningful group of patients would give the Brisbane developer a program that investors can judge on human results.

๐ŸŸข PRODUCT

China Trial of TPST-4003 Should Start This Quarter

TPST-4003 is Tempest's own CAR-T candidate, a type of treatment that re-engineers immune cells. It uses tiny fat particles to carry genetic instructions to those cells, and the biotech designed it "for broad B-cell lineage depletion and reset".

Senlang, its Chinese partner, plans to test it in about 10 people with myasthenia gravis or multiple sclerosis, two nervous-system autoimmune diseases. Tempest still expects the first dose this quarter, the date it gave three months ago.

Senlang runs the trial for $1.5โ€“2.0 million per product, so Tempest gathers human data without its own clinic staff. But the two firms had signed no work order by the end of September.

What to watch: confirmation that the first patient received TPST-4003 by the end of December. A missed date would show that the cash shortage has reached Tempest's clinical work.

๐ŸŸข CASH

Tempest Now Spends About $2 Million a Quarter

Tempest now runs mostly on outside consultants. Between June and September it let go three of its four remaining full-time employees, and research costs fell after it paused older drugs such as amezalpat.

  • Operating loss: $2.8 million, down 21.5% from a year ago
  • Research and development: $0.2 million, down 64%
  • Cash used in operations: about $2.0 million by our math, against $10.4 million in the first half

Lower spending stretches each dollar the biotech raises. But part of the drop came from paused work, because Factor, its main research contractor, sent no invoices after June.

What to watch: fourth-quarter research spending, which now includes a fixed monthly fee to Factor. A figure well above the third-quarter level would show that the savings were only a pause in work.

๐Ÿป Bear Case

๐Ÿ”ด๐Ÿ”ด CASH contradicts narrative

Tempest Owes Fees It Says It Cannot Fund

Chief executive Matt Angel said Tempest secured access to "capital to support our development priorities". The release pointed to an equity line, under which investor Lincoln Park buys new shares when Tempest asks.

The quarterly filing tells a different story. In November Tempest exercised its licence from Chinese partner Senlang, whose yearly fees it does not "currently have the resources to fund", the filing says. It also hired Factor Bioscience, a company Angel controls, for a fixed research fee.

  • Cash on September 30: $0.9 million
  • Equity line share sales in the quarter: $0.3 million
  • Senlang licence fees: $10 million, $12 million and $14 million in years one to three
  • Factor research fee: $5.0 million a year

By our math, first-year fees to Senlang and Factor come to about 17 times the cash on hand. Factor has also pledged $8.9 million of funding, but the filing warns of "significant uncertainty" over whether Tempest can meet its conditions. So the biotech still doubts it can keep operating for another year.

What to watch: whether the annual report next spring shows the first Senlang fee paid. A missed payment would put the rights to TPST-4903, the licensed blood-cancer treatment, at risk.

๐Ÿ”ด GOVERNANCE

Nasdaq Could Remove Tempest From Its Market

Nasdaq requires its listed companies to hold at least $2.5 million of shareholders' equity, the gap between assets and liabilities. Tempest's equity stood at minus $1.8 million in September, so by our math it falls $4.3 million short.

The exchange gave Tempest until November 16 to fix the gap. A second notice followed on November 4, under the minimum bid price rule, and the biotech said it may consider steps "including initiating a reverse stock split".

What to watch: Nasdaq's decision after the November 16 deadline, which Tempest would report in a public filing. A delisting would make each funding route harder, because the equity line and the warrants depend on buyers who can resell their shares.

๐Ÿ”ด CAPITAL ALLOCATION

Warrants Could More Than Double the Share Count

Tempest pays its bills by selling shares and warrants, which are rights to buy shares later at a set price. It had 16.9 million shares at the end of September, against 4.4 million a year earlier.

The filing counts about 20.6 million more shares that warrant holders could claim, and the biotech wrote that these sales "would significantly dilute our stockholders". In October one investor turned warrants into another 3.1 million shares.

Each new share shrinks current owners' claim on any future drug income, and the warrants bring in cash only when holders choose to use them.

What to watch: the share count in the annual report, set against the cash raised. A count that keeps climbing while cash stays low would mean shareholders, not partners, are paying for the new fees.

๐Ÿ”ด PRODUCT

TPST-2003 Is Missing From the Results Release

TPST-2003 re-engineers each patient's own immune cells to attack cancer, a CAR-T approach. Tempest bought it in February from Factor, a company chief executive Matt Angel controls, and Erigen. In April the biotech reported complete responses in all 15 evaluable patients new to CAR-T.

Three months ago Tempest planned a US registrational study, the large trial behind an approval filing, for later this year. The third-quarter release never names TPST-2003, and only the quarterly filing still mentions the goal.

By our math, spending points the other way: Tempest booked no research cost for the program in the quarter. The new contract with Factor covers TPST-4003, TPST-4903 and Senlang work, while the old agreement and work order "have not been terminated but are inactive".

What to watch: whether the annual report keeps a 2026 study start. A delay would leave the licensed TPST-4903 carrying Tempest's cancer work.

๐Ÿ‘“ Other Themes

MACRO

Tempest Blames Markets for Harder Fundraising

Tempest wrote that "potential worsening global economic conditions", inflation and swings in credit markets have made raising money harder. The filing puts no figure on that effect. Its own balance sheet, with liabilities above assets, gives investors reasons of their own to hesitate.

๐Ÿ’ฒ Other KPIs

Unpaid supplier bills (26Q3) $2.0 million
โ‡— accelerating

Accounts payable, the bills Tempest has received but not paid, nearly doubled since December to $2.0 million. They now run at more than twice the cash balance. In October the biotech agreed to settle one $0.7 million balance for $0.2 million. It also owed about $0.2 million of office rent in early November.

Office lease obligations (26Q3) $7.3 million
โ‡˜ decelerating

The rent Tempest still owes on its Brisbane office fell 10.8% since December as the lease term shortened. The lease binds the company through 2030, with payments rising each year. The landlord used the security deposit to cover unpaid rent and asked for it back, which Tempest has not done.

Net loss per share (26Q3) โˆ’$0.21
โ‡˜ decelerating

The loss per share fell to $0.21 from $0.79 a year ago. A larger share count drove that drop, not a smaller loss. The net loss rose 3%, to $3.6 million. Most of the increase came from $0.8 million of costs for setting up the Lincoln Park equity line.

๐Ÿ”ฎ Guidance

TPST-4003 first patient dosed in China trial Q4 2026
๐Ÿ † unchanged from Q4 2026 (first patient enrollment and dosing)
โ‡’ stable

Unchanged. Tempest still plans to give the first patient in its China trial of TPST-4003 a dose before the end of December. The trial should enrol about 10 people. It is the second quarter running with the same date.

TPST-4003 initial clinical data H1 2027
๐Ÿ † unchanged from H1 2027
โ‡’ stable

Unchanged. The plan still has the first results from the China trial arriving in the first half of 2027. That date rests on dosing the first patient this quarter, because doctors need time after each treatment to measure its effect.

TPST-4903 initial Phase 1 data At an upcoming scientific conference (no date given)
โ‡’ stable

New. The biotech plans to present the first results from the early study of TPST-4903, its licensed blood-cancer treatment, at a medical conference. It gave no date, patient count or dose level, so readers cannot yet tell when the data will arrive or how much they will show.

TPST-2003 U.S. registrational study start Later in 2026 (stated in the 10-Q only)
๐Ÿ † unchanged from Later in 2026
โ‡’ stable

Unchanged on paper. The quarterly filing still lists a plan to meet the FDA about a US registrational study later this year. The results release does not mention the program, and less than two months of 2026 remain for both the meeting and the start.

General and administrative expenses About current levels (Q3: $2.6 million)
โ‡’ stable

New. Tempest expects administrative costs to "remain at approximately current levels". By our math, that puts fourth-quarter costs about 26% below a year ago. The outlook leaves out research fees to Factor and Senlang, which now push total spending up.

โ“ Key Questions

Is the TPST-2003 registrational study still planned for 2026?

The quarterly filing still mentions a US study this year, but the release skipped the program and research spending on it stopped after June. Investors need a date or a clear decision.

How will Tempest pay the first Senlang licence fee?

The filing says Tempest lacks the resources to pay the licence fees. Angel should say which source covers the first payment, and what happens to the TPST-4903 rights if it slips.

Did Tempest meet Nasdaq's equity rule by November 16?

Nasdaq set that deadline for the shareholders' equity shortfall. A delisting would make the equity line and warrant exercises harder to use, and those are the main sources of new cash.

How many patients are in the TPST-4903 data?

The release calls the early responses encouraging but gives no patient count, dose or follow-up time. Those details decide whether the licence justifies its yearly fees.

What conditions limit access to Factor's funding pledge?

Tempest warns of significant uncertainty about meeting the pledge's terms. The answer decides whether the money left from Factor, a company the chief executive controls, is available at all.